Show simple item record

dc.contributor.authorPeters, S
dc.contributor.authorDafni, U
dc.contributor.authorBoyer, M
dc.contributor.authorDe, R
dc.contributor.authorFaivre-Finn, Corinne
dc.contributor.authorFelip, E
dc.contributor.authorGarrido, P
dc.contributor.authorGirard, N
dc.contributor.authorGuckenberger, M
dc.contributor.authorHaanen, J
dc.contributor.authorLe, P
dc.contributor.authorMornex, F
dc.contributor.authorOzsahin, M
dc.contributor.authorPaz-Ares, L
dc.contributor.authorPlanchard, D
dc.contributor.authorRaben, D
dc.contributor.authorRamalingam, S
dc.contributor.authorReck, M
dc.contributor.authorSmit, E
dc.contributor.authorStahel, R
dc.contributor.authorStenzinger, A
dc.contributor.authorSwanton, C
dc.contributor.authorVallone, S
dc.contributor.authorGarassino, M
dc.date.accessioned2019-03-04T12:32:45Z
dc.date.available2019-03-04T12:32:45Z
dc.date.issued2019en
dc.identifier.citationPeters S, Dafni U, Boyer M, De Ruysscher D, Faivre-Finn C, Felip E, et al. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Ann Oncol. 2019 Jan 8.en
dc.identifier.pmid30624547en
dc.identifier.doi10.1093/annonc/mdy553en
dc.identifier.urihttp://hdl.handle.net/10541/621580
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdy553en
dc.titlePosition of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).en
dc.typeArticleen
dc.contributor.departmentOncology Department, Lausanne University and CHUV, Switzerlanden
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record